

1 **TITLE:**

2 Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in  
3 small cell lung cancer

4

5 **AUTHORS:**

6 Max Hardy-Werbin<sup>1,12</sup>, Pedro Rocha<sup>2</sup>, Oriol Arpi<sup>1</sup>, Álvaro Taus<sup>2</sup>, Lara Nonell<sup>3</sup>,  
7 Xavier Durán<sup>4</sup>, Xavier Villanueva<sup>2</sup>, Deborah Joseph-Pietras<sup>5</sup>, Luke Nolan<sup>6</sup>,  
8 Sarah Danson<sup>7</sup>, Richard Griffiths<sup>8</sup>, Miguel Lopez-Botet<sup>9,11</sup>, Ana Rovira<sup>1,2</sup>, Joan  
9 Albanell<sup>1,2,11</sup>, Christian Ottensmeier<sup>5,10\*</sup>, Edurne Arriola<sup>1,2\*</sup>

10

11 **AFFILIATIONS:**

12 <sup>1</sup>Cancer Research Program, IMIM (Institut Hospital del Mar d'Investigacions  
13 Mèdiques), Barcelona, Spain; <sup>2</sup>Medical Oncology Department, Hospital del Mar-  
14 CIBERONC, Barcelona, Spain; <sup>3</sup>Microarrays analysis service, IMIM (Institut  
15 Hospital del Mar d'Investigacions Mèdiques), Barcelona, Spain; <sup>4</sup>Statistics  
16 department, IMIM (Institut Hospital del Mar d'Investigacions Mèdiques),  
17 Barcelona, Spain; <sup>5</sup>NIHR Experimental Cancer Medicine Centre, Southampton,  
18 United Kingdom; <sup>6</sup>Medical Oncology Department, University Hospital  
19 Southampton, Southampton, United Kingdom; <sup>7</sup>Sheffield Experimental Cancer  
20 Medicine Centre, Weston Park Hospital, Sheffield, United Kingdom; <sup>8</sup>The  
21 Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, United Kingdom;

1 <sup>9</sup>Immunology unit, IMIM (Institut Hospital del Mar d'Investigacions Mèdiques),  
2 Barcelona, Spain; <sup>10</sup>Cancer Science Unit, Faculty of Medicine, University of  
3 Southampton, Southampton, United Kingdom; <sup>11</sup>Universitat Pompeu Fabra,  
4 Barcelona, Spain; <sup>12</sup>Universitat de Barcelona, Barcelona, Spain; \*These authors  
5 contributed equally to this work

6

7 **CONTACT INFO:**

8

9 **M Hardy-Werbin.** Institut Hospital del Mar d'Investigacions Mèdiques, Dr.  
10 Aiguader 88, PRBB Building, 08003, Barcelona, Spain. mhardy@imim.es

11 **P Rocha.** Medical Oncology Department, Hospital del Mar, Passeig Marítim de  
12 la Barceloneta, 25-29, 08003 Barcelona, Spain. psimoes@parcdesalutmar.cat

13 **O Arpí.** Institut Hospital del Mar d'Investigacions Mèdiques, Dr. Aiguader 88,  
14 PRBB Building, 08003, Barcelona, Spain. oarpi@imim.es

15 **A Taus.** Medical Oncology Department, Hospital del Mar, Passeig Marítim de la  
16 Barceloneta, 25-29, 08003 Barcelona, Spain. ataus@parcdesalutmar.cat

17 **Lara Nonell.** Institut Hospital del Mar d'Investigacions Mèdiques, Dr. Aiguader  
18 88, PRBB Building, 08003, Barcelona, Spain. lnonell@imim.es

19 **Xavier Durán.** Institut Hospital del Mar d'Investigacions Mèdiques, Dr. Aiguader  
20 88, PRBB Building, 08003, Barcelona, Spain. xduran@imim.es

21 **Xavier Villanueva.** Medical Oncology Department, Hospital del Mar, Passeig  
22 Marítim de la Barceloneta, 25-29, 08003 Barcelona, Spain.  
23 xvillanueva@parcdesalutmar.cat

24 **D Joseph-Pietras.** Cancer Science, University of Southampton, University  
25 Road, Southampton, SO17 1BJ, United Kingdom. d.joseph-  
26 pietras@soton.ac.uk

27 **L Nolan.** University Hospital Southampton, Tremona Rd, Southampton SO16  
28 6YD, United Kingdom. luke.nolan@uhs.nhs.uk

29 **S Danson.** Cancer Clinical Trials Centre, Weston Park Hospital, Whitham  
30 Road, Sheffield S10 2SJ, United Kingdom. s.danson@sheffield.ac.uk

- 1 **R Griffiths.** The Clatterbridge Cancer Centre NHS Foundation Trust,  
2 Clatterbridge Road, Bebington, Wirral, CH63 4JY, United Kingdom.  
3 richard.griffiths@clatterbridgecc.nhs.uk
- 4 **M López-Botet.** Institut Hospital del Mar d'Investigacions Mèdiques, Dr.  
5 Aiguader 88, PRBB Building, 08003, Barcelona, Spain. lbotet@imim.es
- 6 **A Rovira.** Institut Hospital del Mar d'Investigacions Mèdiques, Dr. Aiguader 88,  
7 PRBB Building, 08003, Barcelona, Spain. arovira@imim.es
- 8 **J Albanell.** Medical Oncology Department, Hospital del Mar, Passeig Marítim  
9 de la Barceloneta, 25-29, 08003 Barcelona, Spain.  
10 jalbanell@parcdesalutmar.cat
- 11 **CH Ottensmeier.** Cancer Science, University of Southampton, University Road,  
12 Southampton, SO17 1BJ, United Kingdom. c.h.ottensmeier@soton.ac.uk
- 13 **E Arriola.** Medical Oncology Department, Hospital del Mar, Passeig Marítim de  
14 la Barceloneta, 25-29, 08003 Barcelona, Spain. earriola@parcdesalutmar.cat

15

16 **CORRESPONDING AUTHOR:**

17 Dr. Eurne Arriola, Medical Oncology Department, Hospital del Mar, Passeig  
18 Marítim de la Barceloneta, 25-29, 08003 Barcelona, Spain.

19 earriola@parcdesalutmar.cat

20 Telephone: +34-932-483000 Fax: +34-932-483366

21

1 **Disclosure statement:**

2 E.A. and C.O. have received honoraria for consultancy and lectures from  
3 Bristol-Myers Squibb outside of the current work. The remaining authors report  
4 no conflict of interest.

5

6 **Ethics approval and consent to participate:**

7 Sample collection and data analyses were approved by the local ethics  
8 committee of the participating institutions and informed consent of each study  
9 participant. The study was conducted in accordance with the European Good  
10 Clinical Practice requirements (Declaration of Helsinki).

11

12 **Funding:**

13 This work was supported in part by a grant from (1) Fundació La Marató de TV3  
14 (666/C/2013); (2) ISCiii/FEDER (CIBERONC CB16/12/00241, RD12/0036/0051,  
15 PIE15/00008, PI15/00146, PI16/00591, PI13/00140); (3) Xarxa de Bancs de  
16 Tumors (XBTC); (4) Agència de Gestió d'Ajuts Universitaris i de Recerca  
17 (AGAUR), Generalitat de Catalunya (2014SGR740), (5) Fundació Cellex and  
18 (6) Cancer Research UK grant: C491/A12135

19

20

21

22

23

1 **ABSTRACT**

2

3 **Background.** Immunotherapy has shown efficacy in small cell lung cancer  
4 (SCLC), but only a subset of patients benefits. Surrogate biomarkers are urgently  
5 needed. Our aim was to evaluate serum Th1, Th2 and proinflammatory cytokines  
6 in two cohorts of SCLC patients before and during treatment with chemotherapy  
7 with or without ipilimumab and to correlate them with survival.

8 **Patients and methods.** Two cohorts of SCLC patients were studied: patients  
9 treated with chemotherapy (n=47), and patients treated with chemotherapy plus  
10 ipilimumab (n=37). Baseline, on-treatment and after-treatment serum samples  
11 were evaluated for the presence of IL-1beta, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IFN-  
12 gamma, TNFalpha, GM-CSF and Mip-1alpha using a Luminex assay. Differential  
13 changes of cytokines between cohorts were analyzed. Associations between  
14 cytokine levels and their changes with overall survival were evaluated.

15 **Results.** Patients treated with ipilimumab showed a global increase of all  
16 cytokines after treatment initiation. A high level of IL-8 at baseline was associated  
17 with worse prognosis regardless of treatment. Baseline increased IL-2 levels  
18 predicted sensitivity to ipilimumab, while high IL-6 and TNFalpha predicted  
19 resistance. An on-treatment increase in IL-4 levels in patients treated with  
20 immune-chemotherapy was associated with a better overall survival.

21 **Conclusions.** The addition of ipilimumab to standard chemotherapy in SCLC  
22 modulates the serum levels of cytokines. Baseline levels and their change over  
23 time relate to overall survival. Blood based biomarkers are convenient for patients

1 and our results support prospective validation of cytokines as predictive  
2 biomarkers for ipilimumab in SCLC.

3

4 **Keywords:**

5 Small cell lung cancer, ipilimumab, cytokines, immunotherapy, biomarkers

6

7

## 1 INTRODUCTION

2 Small cell lung cancer (SCLC) is the most aggressive type of lung cancer.  
3 Platinum-based chemotherapy has been the standard of care for the last three  
4 decades and unfortunately varying combinatorial systemic approaches have not  
5 improved survival <sup>1,2</sup>. The substantial incidence of autoimmune paraneoplastic  
6 immune events <sup>3</sup> and the high tumor mutational burden <sup>4</sup> suggest that immune  
7 modulation is a promising strategy in SCLC <sup>5</sup>.

8 Consistent with these concepts, immune checkpoint inhibitors have shown  
9 some activity in SCLC <sup>6-10</sup>. Ipilimumab, a fully human immunoglobulin G1  
10 monoclonal that blocks CTLA-4 <sup>11</sup>, showed a trend to improved overall survival  
11 (OS) when combined with standard chemotherapy in a phase II trial <sup>6</sup>. Although  
12 the confirmatory phase III failed to confirm an improvement in OS <sup>2</sup>,  
13 combination of anti-CTLA4 and anti-PD1 agents showed a significant antitumor  
14 activity in SCLC patients in second line of treatment, particularly when  
15 ipilimumab is included in the regime <sup>7</sup>.

16 However, two more recent studies of the combination in the maintenance and  
17 second line settings have failed to demonstrate benefit over standard  
18 approaches <sup>12,13</sup>. These failed trials have not used any biomarkers for selection  
19 of patients with higher likelihood of benefit and unfortunately this may preclude  
20 these drugs to get to the clinic. Despite this, there is a subset of patients who  
21 benefit from immunotherapy and have long term outcomes when this strategy is  
22 used <sup>2,9</sup>. Predictive biomarkers to select patients who will benefit from  
23 immunotherapy are therefore urgently needed. In SCLC additionally the limited

1 tissue available for biomarker studies <sup>14</sup> makes blood-based tests particularly  
2 interesting and relevant.

3 Cytokines are soluble molecular messengers with a crucial role in immune  
4 response signaling <sup>15</sup>. While Th1 cytokines (IL-2, IFN $\gamma$  and TNF $\alpha$ ) elicit cell-  
5 mediated responses, Th2 cytokines (IL-4, IL-5, and IL-10) direct the T-cell  
6 response away from a protective Th1 phenotype <sup>16,17</sup>. The Th1/Th2 cytokine  
7 balance is disrupted in malignant tumors <sup>18-20</sup> favoring an immunosuppressive  
8 microenvironment. There are preliminary data supporting a prognostic role of  
9 inflammatory cytokines such as IL-6 and IL-8 in NSCLC <sup>21,22</sup>. However, the  
10 biological impact of cytokine levels has to date not been evaluated in SCLC.

11 We analyzed serum Th1, Th2 and inflammatory cytokines in two independent  
12 cohorts of SCLC patients treated with standard chemotherapy with or without  
13 the anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) monoclonal antibody  
14 ipilimumab. Our goal was to evaluate if baseline levels of cytokines or changes  
15 induced by therapy would predict benefit from the addition of ipilimumab in  
16 SCLC and allow insights into the immunological consequence of the addition of  
17 a checkpoint inhibitor.

18



# 1 RESULTS

## 2 Patients' characteristics and outcomes

3 We included 84 SCLC patients. Cohort 1 consisted of 47 patients treated with  
4 platinum – etoposide; cohort 2 included 37 patients treated with platinum –  
5 etoposide in combination with ipilimumab 10mg/kg. Patients' characteristics are  
6 summarized in Supplementary table S1. Cohort 1 included more men (74.5% vs  
7 64.9%), patients with performance status (PS)=2 (7% vs 0%) and patients with  
8 limited disease (25% vs 0%). Median progression free survival (PFS) was 6.8  
9 months (m) in cohort 1 and 6.9m in cohort 2; median overall survival (OS) was  
10 13.3m in cohort 1 and 17m in cohort 2.

11

## 12 Serum Th1, Th2 and pro-inflammatory cytokines are lower in SCLC 13 patients than in a cohort of healthy individuals

14 We evaluated pre-treatment serum cytokine levels in SCLC patients (both  
15 cohorts combined) in comparison to healthy volunteers. IL-1 $\beta$ , IL-5, Mip-1 $\alpha$  and  
16 TNF $\alpha$  were significantly lower in SCLC patients compared with healthy  
17 volunteers (Figure 1; Supplementary Table S2). The remaining cytokines except  
18 IL-6, were also numerically lower in SCLC but the difference was not statistically  
19 significant. When we restricted the analyses to patients with extensive disease,  
20 serum levels of IL-1 $\beta$ , IL-4, IL-5 and Mip-1 $\alpha$  were significantly lower in SCLC  
21 patients when compared with healthy volunteers.

22

## 1 **Baseline cytokine levels correlate with age, PS and stage**

2 We assessed the correlation between the level of cytokines (both cohorts) and  
3 clinical features. Baseline levels of  $\text{TNF}\alpha$  were significantly higher in patients  
4 over 60 years old; IL-5 was significantly higher in patients with PS 0 vs PS 1/2  
5 and IL-2 was significantly higher in female patients compared with male  
6 (Supplementary Figure S1). IL-4 and Mip-1 $\alpha$  were significantly lower in patients  
7 with extensive disease when compared to those with limited disease  
8 (Supplementary Figure S2).

9

## 10 **Ipilimumab globally increases Th1, Th2 and inflammatory cytokines**

11 We next studied how cytokine levels changed once treatment had been started  
12 in each cohort. Patients treated with chemotherapy alone, showed a decrease  
13 of GM-CSF,  $\text{IFN}\gamma$ , Mip-1 $\alpha$ , IL-1 $\beta$ , IL-2, IL-6 and IL-8 median concentration from  
14 baseline to tumor response;  $\text{TNF}\alpha$ , IL-5 and IL-10 showed an increase from  
15 baseline to tumor response; and IL-4 levels showed no significant changes.

16 Patients treated with immunochemotherapy showed a global increase of all  
17 cytokines assessed (IL-1 $\beta$ , IL-2, IL-4, IL-5, IL-6, IL-8, IL-10,  $\text{IFN}\gamma$ ,  $\text{TNF}\alpha$ , Mip-1 $\alpha$   
18 and GM-CSF) (Figure 2A and 2B) (Supplementary Table S3). These differences  
19 between cohorts were statistically significant for all cytokines except for GM-  
20 CSF and IL-8.

21 We calculated the percentages of cytokine variation from the first to the second  
22 time-point using previously log<sub>2</sub> transformed data. A heatmap of the changes in

1 cytokine levels after treatment, compared to baseline is displayed in Figure 2C.  
2 In patients treated with immunochemotherapy, the dominant effect is an  
3 increase on cytokine levels in contrast to a reduction after chemotherapy alone.  
4 Consistent with this, a principal component analysis (PCA) of fold change of  
5 cytokine levels after treatment reveals that patients cluster according to the  
6 treatment received (chemotherapy alone vs immunotherapy) (Figure 2D).

7

### 8 **Baseline IL-8 levels are an unfavorable prognostic marker in SCLC** 9 **regardless of treatment**

10 We inquired whether basal levels of cytokines correlated with survival in SCLC.  
11 In both cohorts, patients with serum IL-8 concentration above cut-off, had a  
12 worse OS. In cohort 1, patients with baseline IL-8 above cut-off had a median  
13 OS of 9.2m vs 16.8m of those with lower levels ( $p=0.028$ ); in cohort 2, patients  
14 with baseline IL-8 above cut-off had a median OS of 5.3m vs 17m of those with  
15 lower levels ( $p=0.031$ ) (Figure 3). When restricting the analyses to the  
16 advanced disease population we obtained the same outcome.

17

### 18 **Baseline IL-2 levels predict sensitivity to ipilimumab, while IL-6 and TNF $\alpha$** 19 **predict resistance**

20 We evaluated the potential predictive role of cytokines in patients treated with  
21 ipilimumab. Patients treated with immunochemotherapy with a serum IL-2  
22 concentration above cut-off at baseline, had a median OS of 30.5m while those

1 with lower levels had a median OS of 8m (p=0.015) (Figure 4A). In contrast,  
2 patients with a serum IL-6 above cut-off had a median OS of 9.5m while those  
3 with lowers levels was 18.5m (p=0.026) (Figure 4B). Patients with a serum  
4 TNF $\alpha$  concentration above cut-off had a median OS of 7.8m while those with  
5 lower levels was 18.5m (p=0.004) (Figure 4C). These associations were not  
6 observed when patients were treated with chemotherapy alone. When we  
7 restricted the analyses to the advanced disease population, all these results  
8 were sustained. Similar results were find when the median cytokine serum level  
9 was used as a cut-off (Supplementary Table S4). The multivariate analyses  
10 showed that high levels of IL-2 were independently associated with sensitivity to  
11 ipilimumab and high levels of IL-6 and TNF $\alpha$  were independently associated  
12 with resistance to ipilimumab (Supplementary Table S5).

13

#### 14 **Changes in IL-4 levels during treatment link to outcome in SCLC**

15 We hypothesized that quantitative changes in cytokine levels during treatment  
16 could be associated with survival. Patients treated with chemotherapy alone  
17 whose IL-4 increased more than 23% from baseline to response, had a  
18 significant worse OS (9.5m vs 16.3m; p=0.001). This finding was maintained  
19 when analyzing only the advanced patients, although it lost statistical  
20 significance (p=0.063). However, those treated with immunochemotherapy  
21 whose IL-4 increased more than 32% had a significant better OS (18.5m vs  
22 8.8m; p=0.042) (Figure 5).

23

## 1 **DISCUSSION**

2 To the best of our knowledge, this is the first study to assess how ipilimumab  
3 affects serum levels of immunomodulatory cytokines in SCLC. Our access to  
4 two cohorts of patients who were treated with either immunochemotherapy or  
5 chemotherapy alone allowed us to assess the biological effect of the addition of  
6 ipilimumab and to interrogate these data in the light of clinical outcomes.

7 An intriguing result is the observation of concordantly lower serum levels of  
8 multiple cytokines in SCLC patients compared to healthy controls. In the  
9 literature we only found 3 patients that had been evaluated in this way <sup>23</sup>; a  
10 functional study on whole blood stimulated in vitro revealed a lower cytokine  
11 release in cells from SCLC patients, perhaps offering an insight into the  
12 underpinning biology of our observation <sup>24</sup>. More data are available on  
13 circulating IL-6 levels: a study of 72 patients with SCLC identified that in both  
14 limited and extensive disease, elevated IL6 levels could be detected, consistent  
15 with our observation <sup>25</sup>.

16 The modulation of cytokine levels after treatment with immunochemotherapy  
17 has not been previously reported in SCLC. We found that addition of ipilimumab  
18 increased concentrations of the evaluated cytokines globally and appeared to  
19 counteract the effect of chemotherapy that typically decreased cytokines. It is  
20 recognized that SCLC cells may be the source of cytokines and therefore  
21 successful treatment could reduce levels as observed for the majority of  
22 cytokines. This might not be the main source, except for IL-6, as the  
23 pretreatment levels in patients are already lower than in healthy controls.

1 Immune cells are also sources of cytokines and can be affected by  
2 chemotherapy-induced apoptosis, likely contributing to the observed decrease.  
3 Notably, however, patients treated with chemotherapy alone showed  
4 stabilization or increase in levels of TNF $\alpha$  and Th2 cytokines. These data  
5 suggest that the important compartment of cells contributing to the presence of  
6 these cytokines might not be affected by chemotherapy, for example M2  
7 macrophages in the tumor microenvironment <sup>26,27</sup>. In the absence of paired  
8 samples of tumor tissue, we were unable to evaluate this directly. Ipilimumab  
9 has previously been reported to increase secretion of IFN- $\gamma$ , IL-2R, IL-12, and  
10 IL-13 from PBMC in vitro exposure <sup>28</sup>, consistent with its proposed release of  
11 activated T-cells from inhibition.

12 Next, we explored the prognostic and predictive role of cytokine levels at  
13 baseline and during treatment. IL-8 is secreted by malignant cells and tumor  
14 stroma cells; anti-IL-8 antibodies have shown activity in vitro and in vivo <sup>29</sup> and it  
15 is being currently tested in clinical trials (NCT02536469). We found that high  
16 baseline levels of IL-8 were associated with worse OS regardless of treatment  
17 type. This is consistent with previous literature and is probably a surrogate of  
18 tumor burden as it showed a profound decrease with chemotherapy <sup>30</sup>.

19 Interestingly, IL-8 was minimally affected by the addition of ipilimumab. IL-8 has  
20 been

21 To evaluate the predictive value of cytokine levels after immunochemotherapy,  
22 we analyzed the changes in serum concentrations of each cytokine and  
23 compared the effect on outcome in both cohorts. Although the cohorts have

1 differences in baseline clinical characteristics, the possibility of comparing the  
2 effects of the combination to chemotherapy alone (standard treatment in SCLC  
3 up to date) provided the opportunity to individualize the effects related to  
4 ipilimumab. Only associations that were significant for the ipilimumab treated  
5 cohort and were different from those observed in the chemotherapy only arm,  
6 were considered predictive of ipilimumab-linked effects. For instance, serum IL-  
7 2 behaved as a predictor of benefit to ipilimumab, and elevated baseline levels  
8 identified patients with a significant longer OS. No such a difference was  
9 observed in patients treated with chemotherapy alone. IL-2 is a cytokine that  
10 promotes the proliferation of T cells, supporting the initiation and maintenance  
11 of immune response <sup>31</sup>. Moreover, it stimulates the proliferation of natural killer  
12 cells and enhances their activity <sup>32</sup>. As the regulation of T-cell activation through  
13 binding of CTLA4 to B7 may affect IL-2 secretion <sup>33</sup>, the release of this blockade  
14 with ipilimumab would increase IL-2 concentration enhancing the immune  
15 response, and could explain the observed better outcome. In contrast, IL-6 and  
16 TNF $\alpha$  behaved as predictors of resistance to ipilimumab: patients with higher  
17 baseline concentrations treated with immunochemotherapy had a shorter OS.  
18 Our data are consistent with observations in other solid cancers: IL-6 has been  
19 associated with tumor progression in lung cancer <sup>34</sup> and to a lack of benefit from  
20 ipilimumab in melanoma <sup>35,36</sup>. Moreover, it has been tested as a target in cancer  
21 in vivo <sup>37</sup>. TNF $\alpha$  has pro-tumorigenic activity in cancer <sup>38</sup> and has been linked to  
22 MAPK inhibitor resistance in melanoma when secreted by macrophages.  
23 Increased serum TNF $\alpha$  might reflect an immunosuppressive tumor

1 microenvironment explaining the observed associated resistance to ipilimumab.  
2 Although these mechanisms seem plausible, they require further validation.  
3 As serial sampling was available in both cohorts, we evaluated if changes in the  
4 cytokine serum levels could predict for benefit from ipilimumab. Our results  
5 showed that IL-4 levels were not significantly modified in patients treated with  
6 chemotherapy alone. In patients treated with chemotherapy in whom IL-4  
7 increased we observed a worse overall survival. It is possible that this may be  
8 reflecting an effect on macrophage M2 polarization <sup>39</sup>. Interestingly, IL-4  
9 increased in the ipilimumab treated cohort and patients experiencing this  
10 increase had a better outcome. This increase has been observed in mice  
11 treated with ipilimumab but an association with outcome is not observed after  
12 ipilimumab monotherapy <sup>40,41</sup>. However, the evidence of the pro or antitumoral  
13 role of IL-4 in the literature is contradictory and its function seems to depend on  
14 IL-4 levels and its association with other immunological modulators <sup>42</sup>. Globally,  
15 our results are novel and hypothesis generating, but warrant prospective  
16 validation.

17 In conclusion, we have observed differential impact of ipilimumab in serum  
18 cytokines in patients with SCLC. Baseline levels and changes on treatment  
19 might serve as convenient predictive biomarkers of benefit from adding  
20 ipilimumab to chemotherapy in a disease where tumor biomarkers studies are  
21 challenging.

22



# 1 PATIENTS AND METHODS

## 2 Patients and study design

3 We retrospectively evaluated two independent cohorts of SCLC patients whose  
4 outcomes we have previously reported <sup>43</sup>. Patients from cohort 1 were recruited  
5 between November of 2009 and January of 2014 at the Hospital del Mar,  
6 Barcelona and treated with platinum plus etoposide <sup>44,45</sup>. Cohort 2 included  
7 patients recruited to a phase II trial of ipilimumab at 10mg/kg, platinum and  
8 etoposide (ICE-trial) <sup>9</sup>. We included a control donor population of healthy, age-  
9 and sex-matched individuals ( $n=30$ ). Sample collection and data analyses were  
10 approved by the local ethics committee of the participating institutions and  
11 informed consent of each study participant was obtained.

12

## 13 Sample collection

14 Serum samples were sequentially collected in each cohort: for cohort 1 at  
15 baseline (before starting treatment), at first response evaluation (at 3 months  
16 approximately) and at progression; for cohort 2 at baseline, at 3 and 6 months.  
17 Whole blood samples were collected by standard venipuncture techniques  
18 using serum separator tubes. Samples were allowed to clot for 30 minutes at  
19 room temperature before centrifugation for 10 minutes at 1000 g at 4 C.  
20 Following centrifugation, the supernatant (serum) was immediately removed  
21 and assayed immediately or aliquoted and stored frozen at -80 C until further  
22 use.

1

## 2 **Cytokine assessment**

3 Serum samples of all patients and healthy donors were evaluated using a  
4 commercially Milliplex map Human High Sensitivity T Cell magnetic bead panel  
5 (Millipore, Billerica, MA, USA) coupled with the Luminex xMAP platform. We  
6 measured a panel of Th1 (IFN $\gamma$ , IL-2, TNF $\alpha$ ), Th2 (IL-4, IL-5, IL-10), and  
7 inflammatory cytokines (GM-CSF, IL-1 $\beta$ , IL-6, IL-8) plus MIP-1 $\alpha$  in accordance  
8 with the manufacturer's instructions. Data was analyzed using five-parametric  
9 curve fitting and assay controls included kit standards and Multiplex controls.  
10 Intra-assay variabilities were less than 12%. Duplicate measurements with a  
11 variability higher than 35% were excluded. These experiments were supervised  
12 by technical personal of the Luminex Core Facility at IMIM.

13

## 14 **Cytokine cut-off calculation**

15 To evaluate the association of cytokines levels with survival, we evaluated the  
16 impact of different cut-off methods, including medians (Supplementary Table  
17 S4) and ROC curves (Supplementary Table S6 and Supplementary Figure S3).  
18 Finally, as the endpoint for comparison was overall survival, we used the web-  
19 based software Cut-off Finder <sup>46</sup>, previously used in the literature <sup>47,48</sup>. This  
20 method takes into account this endpoint outcome: for each cytokine we  
21 identified the threshold level at which a log-rank test allowed segregation of  
22 patients into groups with good and poor outcomes (Supplementary Table S7).

1 Then we calculated the percentage of cytokine median concentration variation  
2 from first to second time-point and considered >5% positive or negative  
3 variations as significant changes (Supplementary Table S8).

4

## 5 **Statistical analyses**

6 Statistical analysis was carried out using Stata/MP 14 (StataCorp LLC, Texas,  
7 USA) and Prism 7.0c (GraphPad Software, Inc.). Baseline values of cytokines  
8 were compared among cohorts and healthy volunteers using the non-  
9 parametric Mann-Whitney U-test. Overall survival, measured from date of start  
10 of treatment until date of death or last visit, was plotted by the Kaplan-Meier  
11 method and curves were compared with the log-rank test. All tests were  
12 conducted at the two-sided test with 0.05 level of significance. R (v 3.4.3) was  
13 used to log<sub>2</sub> transform data, compute cytokine variation and to generate heat  
14 maps (using package gplots) and principal component analysis (PCA).

15

16

17

18

19

## 1 REFERENCES

- 2 1. Oze I, Hotta K, Kiura K, Ochi N, Takigawa N, Fujiwara Y, Tabata M,  
3 Tanimoto M. Twenty-seven years of phase III trials for patients with extensive  
4 disease small-cell lung cancer: disappointing results. PLoS One.  
5 2009;4(11):e7835. doi:10.1371/journal.pone.0007835
- 6 2. Reck M, Luft A, Szczesna A, Havel L, Kim SW, Akerley W, Pietanza MC, Wu  
7 YL, Zielinski C, Thomas M, et al. Phase III randomized trial of ipilimumab plus  
8 etoposide and platinum versus placebo plus etoposide and platinum in  
9 extensive-stage small-cell lung cancer. J. Clin. Oncol. 2016;34(31):3740–3748.  
10 doi:10.1200/JCO.2016.67.6601
- 11 3. Darnell RB, Posner JB. Paraneoplastic syndromes and the nervous system.  
12 N. Engl. J. Med. 2003;3(4):287–288. doi:10.1056/NEJMra023009
- 13 4. Miller CW, Simon K, Aslo A, Kok K, Yokota J, Buys CH, Terada M, Koeffler  
14 HP. p53 mutations in human lung tumors. Cancer Res. 1992;52(7):1695–8.
- 15 5. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W,  
16 Yuan J, Wong P, Ho TS, et al. Mutational landscape determines sensitivity to  
17 PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124–8.  
18 doi:10.1126/science.aaa1348
- 19 6. Reck M, Bondarenko I, Luft A, Serwatowski P, Barlesi. F, Chacko R,  
20 Sebastian M, Lu H, Cuillerot JM, Lynch TJ. Ipilimumab in combination with  
21 paclitaxel and carboplatin as first-line therapy in extensivedisease-small-cell  
22 lungcancer: Results from a randomized, double-blind, multicenter phase 2 trial.

- 1 Ann. Oncol. 2013;24(1):75–83. doi:10.1093/annonc/mds213
- 2 7. Antonia SJ, López-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP, Jäger D,  
3 Pietanza MC, Le DT, de Braud F, et al. Nivolumab alone and nivolumab plus  
4 ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre,  
5 open-label, phase 1/2 trial. *Lancet. Oncol.* 2016;17(7):883–895.  
6 doi:10.1016/S1470-2045(16)30098-5
- 7 8. Ott PA, Elez E, Hirt S, Kim D-W, Morosky A, Saraf S, Piperdi B, Mehnert  
8 JM. Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer:  
9 Results From the Phase Ib KEYNOTE-028 Study. *J. Clin. Oncol.*  
10 2017;35(34):3823–3829. doi:10.1200/JCO.2017.72.5069
- 11 9. Arriola E, Wheeler M, Galea I, Cross N, Maishman T, Hamid D, Stanton L,  
12 Cave J, Geldart T, Mulatero C, et al. Outcome and Biomarker Analysis from a  
13 Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and  
14 Etoposide as First-Line Therapy for Extensive-Stage SCLC. *J. Thorac. Oncol.*  
15 2016;11(9):1511–21. doi:10.1016/j.jtho.2016.05.028
- 16 10. Horn L, Mansfield AS, Szczęśna A, Havel L, Krzakowski M, Hochmair MJ,  
17 Huemer F, Losonczy G, Johnson ML, Nishio M, et al. First-Line Atezolizumab  
18 plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. *N. Engl. J.*  
19 *Med.* 2018;NEJMoa1809064. doi:10.1056/NEJMoa1809064
- 20 11. Ku GY, Yuan J, Page DB, Schroeder SEA, Panageas KS, Carvajal RD,  
21 Chapman PB, Schwartz GK, Allison JP, Wolchok JD. Single-institution  
22 experience with ipilimumab in advanced melanoma patients in the

1 compassionate use setting: lymphocyte count after 2 doses correlates with  
2 survival. *Cancer*. 2010;116(7):1767–75. doi:10.1002/cncr.24951

3 12. Bristol-Myers Squibb Announces CheckMate -451 Study Did Not Meet  
4 Primary Endpoint of Overall Survival with Opdivo Plus Yervoy Vs. Placebo as A  
5 Maintenance Therapy in Patients with Extensive-Stage Small Cell Lung Cancer  
6 After Completion of First-Line. [https://news.bms.com/press-](https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibb-announces-checkmate-451-study-did-not-mee)  
7 [release/corporatefinancial-news/bristol-myers-squibb-announces-checkmate-](https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibb-announces-checkmate-451-study-did-not-mee)  
8 [451-study-did-not-mee](https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibb-announces-checkmate-451-study-did-not-mee)

9 13. Bristol-Myers Squibb Announces Phase 3 CheckMate -331 Study Does Not  
10 Meet Primary Endpoint of Overall Survival with Opdivo Versus Chemotherapy in  
11 Patients with Previously Treated Relapsed Small Cell Lung Cancer.  
12 [https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-](https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibb-announces-phase-3-checkmate-331-study-doe)  
13 [squibb-announces-phase-3-checkmate-331-study-doe](https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibb-announces-phase-3-checkmate-331-study-doe)

14 14. Travis WD. Pathology and Diagnosis of Neuroendocrine Tumors: Lung  
15 Neuroendocrine. *Thorac. Surg. Clin.* 2014;24(3):257–266.  
16 doi:10.1016/j.thorsurg.2014.04.001

17 15. Lee S, Margolin K. Cytokines in cancer immunotherapy. *Cancers (Basel)*.  
18 2011;3(4):3856–3893. doi:10.3390/cancers3043856

19 16. Paul WE, Seder RA. Lymphocyte responses and cytokines. *Cell*.  
20 1994;76(2):241–251. doi:10.1016/0092-8674(94)90332-8

21 17. Huang M, Wang J, Lee P, Sharma S, Mao JT, Meissner H, Uyemura K,  
22 Modlin R, Wollman J, Dubinett SM. Human non-small cell lung cancer cells

- 1 express a type 2 cytokine pattern. *Cancer Res.* 1995;55(17):3847–53.  
2 doi:10.1016/0169-5002(96)85851-X
- 3 18. Hong CC, Yao S, McCann SE, Dolnick RY, Wallace PK, Gong Z, Quan L,  
4 Lee KP, Evans SS, Repasky EA, et al. Pretreatment levels of circulating Th1  
5 and Th2 cytokines, and their ratios, are associated with ER-negative and triple  
6 negative breast cancers. *Breast Cancer Res. Treat.* 2013;139(2):477–488.  
7 doi:10.1007/s10549-013-2549-3
- 8 19. Lucey DR, Clerici M, Shearer GM. Type 1, and Type 2 cytokine  
9 dysregulation in human infectious, neoplastic, and inflammatory diseases. *Clin.*  
10 *Microbiol. Rev.* 1996;9(4):532–562.
- 11 20. Lippitz BE. Cytokine patterns in patients with cancer: A systematic review.  
12 *Lancet Oncol.* 2013;14(6):218–28. doi:10.1016/S1470-2045(12)70582-X
- 13 21. Pine SR, Mechanic LE, Enewold L, Chaturvedi AK, Katki HA, Zheng YL,  
14 Bowman ED, Engels EA, Caporaso NE, Harris CC. Increased levels of  
15 circulating interleukin 6, interleukin 8, c-reactive protein, and risk of lung cancer.  
16 *J. Natl. Cancer Inst.* 2011;103(14):1112–1122. doi:10.1093/jnci/djr216
- 17 22. Sanmamed MF, Perez-Gracia JL, Schalper KA, Fusco JP, Gonzalez A,  
18 Rodriguez-Ruiz ME, Oñate C, Perez G, Alfaro C, Martín-Algarra S, et al.  
19 Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-  
20 PD-1 treatment in melanoma and non-small-cell lung cancer patients. *Ann.*  
21 *Oncol.* 2017;28(8):1988–1995. doi:10.1093/annonc/mdx190
- 22 23. Matanić D, Beg-Zec Z, Stojanović D, Matakorić N, Flego V, Milevoj-Ribić F.

- 1 Cytokines in patients with lung cancer. *Scand. J. Immunol.* 2003;57(2):173–  
2 178. doi:10.1046/j.1365-3083.2003.01205.x
- 3 24. Fischer JR, Schindel M, Stein N, Lahm H, Gallati H, Krammer PH, Drings P.  
4 Selective suppression of cytokine secretion in patients with small-cell lung  
5 cancer. *Ann. Oncol. Off. J. Eur. Soc. Med. Oncol.* 1995;6(9):921–6.
- 6 25. Wójcik E, Jakubowicz J, Skotnicki P, Sas-Korczyńska B, Kulpa JK. IL-6 and  
7 VEGF in small cell lung cancer patients. *Anticancer Res.* 2010;30(5):1773–  
8 1778.
- 9 26. Kitajima M, Ziegler SF. Cutting Edge: Identification of the Thymic Stromal  
10 Lymphopoietin-Responsive Dendritic Cell Subset Critical for Initiation of Type 2  
11 Contact Hypersensitivity. *J. Immunol.* 2013;191(10):4903–4907.  
12 doi:10.4049/jimmunol.1302175
- 13 27. Dijkgraaf EM, Heusinkveld M, Tummers B, Vogelpoel LTC, Goedemans R,  
14 Jha V, Nortier JWR, Welters MJP, Kroep JR, Van Der Burg SH. Chemotherapy  
15 alters monocyte differentiation to favor generation of cancer-supporting m2  
16 macrophages in the tumor microenvironment. *Cancer Res.* 2013;73(8):2480–  
17 2492. doi:10.1158/0008-5472.CAN-12-3542
- 18 28. Yano H, Thakur A, Tomaszewski EN, Choi M, Deol A, Lum LG. Ipilimumab  
19 augments antitumor activity of bispecific antibody-armed T cells. *J. Transl. Med.*  
20 2014;12(1):1–11. doi:10.1186/1479-5876-12-191
- 21 29. Huang S, Mills L, Mian B, Tellez C, McCarty M, Yang X-D, Gudas JM, Bar-  
22 Eli M. Fully Humanized Neutralizing Antibodies to Interleukin-8 (ABX-IL8) Inhibit



- 1 Angiogenesis, Tumor Growth, and Metastasis of Human Melanoma. *Am. J.*  
2 *Pathol.* 2002;161(1):125–134. doi:10.1016/S0002-9440(10)64164-8
- 3 30. Young RJ, Tin AW, Brown NJ, Jitlal M, Lee SM, Woll PJ. Analysis of  
4 circulating angiogenic biomarkers from patients in two phase III trials in lung  
5 cancer of chemotherapy alone or chemotherapy and thalidomide. *Br. J. Cancer.*  
6 2012;106(6):1153–1159. doi:10.1038/bjc.2012.50
- 7 31. Dembic Z. Cytokines of the Immune System. *Cytokines Immune Syst.*  
8 2015;143–239. doi:10.1016/B978-0-12-419998-9.00006-7
- 9 32. Henney CS, Kuribayashi K, Kern DE, Gillis S. Interleukin-2 augments  
10 natural killer cell activity. *Nature.* 1981;291(5813):335–338.  
11 doi:10.1038/291335a0
- 12 33. Krummel MF, Allison JP. CTLA-4 engagement inhibits IL-2 accumulation  
13 and cell cycle progression upon activation of resting T cells. *J. Exp. Med.*  
14 1996;183(6):2533–40. doi:10.1084/jem.183.6.2533
- 15 34. Chang CH, Hsiao CF, Yeh YM, Chang GC, Tsai YH, Chen YM, Huang MS,  
16 Chen HL, Li YJ, Yang PC, et al. Circulating interleukin-6 level is a prognostic  
17 marker for survival in advanced nonsmall cell lung cancer patients treated with  
18 chemotherapy. *Int. J. Cancer.* 2013;132(9):1977–1985. doi:10.1002/ijc.27892
- 19 35. Damuzzo V, Solito S, Pinton L, Carrozzo E, Valpione S, Pigozzo J, Arboretti  
20 Giancristofaro R, Chiarion-Sileni V, Mandruzzato S. Clinical implication of  
21 tumor-associated and immunological parameters in melanoma patients treated  
22 with ipilimumab. *Oncoimmunology.* 2016;5(12):e1249559.

- 1 doi:10.1080/2162402X.2016.1249559
- 2 36. Bjoern J, Juul Nitschke N, Zeeberg Iversen T, Schmidt H, Fode K, Svane  
3 IM. Immunological correlates of treatment and response in stage IV malignant  
4 melanoma patients treated with Ipilimumab. *Oncoimmunology*.  
5 2016;5(4):e1100788. doi:10.1080/2162402X.2015.1100788
- 6 37. Gopinathan G, Milagre C, Pearce OMT, Reynolds LE, Hovalala-Dilke K,  
7 Leinster DA, Zhong H, Hollingsworth RE, Thompson R, Whiteford JR, et al.  
8 Interleukin-6 stimulates defective angiogenesis. *Cancer Res*.  
9 2015;75(15):3098–3107. doi:10.1158/0008-5472.CAN-15-1227
- 10 38. Martínez-Reza I, Díaz L, García-Becerra R. Preclinical and clinical aspects  
11 of TNF- $\alpha$  and its receptors TNFR1 and TNFR2 in breast cancer. *J. Biomed. Sci*.  
12 2017;24(1):1–8. doi:10.1186/s12929-017-0398-9
- 13 39. Rahal OM, Wolfe AR, Mandal PK, Larson R, Tin S, Jimenez C, Zhang D,  
14 Horton J, Reuben JM, McMurray JS, et al. Blocking Interleukin (IL)4- and IL13-  
15 Mediated Phosphorylation of STAT6 (Tyr641) Decreases M2 Polarization of  
16 Macrophages and Protects Against Macrophage-Mediated Radioresistance of  
17 Inflammatory Breast Cancer. *Int. J. Radiat. Oncol. Biol. Phys*.  
18 2018;100(4):1034–1043. doi:10.1016/j.ijrobp.2017.11.043
- 19 40. Redmond WL, Linch SN, Kasiewicz MJ. Combined Targeting of  
20 Costimulatory (OX40) and Coinhibitory (CTLA-4) Pathways Elicits Potent  
21 Effector T Cells Capable of Driving Robust Antitumor Immunity. *Cancer*  
22 *Immunol. Res*. 2014;2(2):142–153. doi:10.1158/2326-6066.CIR-13-0031-T

- 1 41. Linch SN, Redmond WL. Combined OX40 ligation plus CTLA-4 blockade:  
2 More than the sum of its parts. *Oncoimmunology*. 2014;3(3):11–13.  
3 doi:10.4161/onci.28245
- 4 42. Li Z, Chen L, Qin Z. Paradoxical roles of IL-4 in tumor immunity. *Cell. Mol.*  
5 *Immunol.* 2009;6(6):415–422. doi:10.1038/cmi.2009.53
- 6 43. Hardy-Werbin M, Arpi O, Taus A, Rocha P, Joseph-Pietras D, Nolan L,  
7 Danson S, Griffiths R, Lopez-Botet M, Rovira A, et al. Assessment of neuronal  
8 autoantibodies in patients with small cell lung cancer treated with chemotherapy  
9 with or without ipilimumab. *Oncoimmunology*. 2018;7(2):e1395125.  
10 doi:10.1080/2162402X.2017.1395125
- 11 44. Cañadas I, Taus Á, Villanueva X, Arpi O, Pijuan L, Rodríguez Y, Menéndez  
12 S, Mojal S, Rojo F, Albanell J, et al. Angiopoietin-2 is a negative prognostic  
13 marker in small cell lung cancer. *Lung Cancer*. 2015;90(2):302–6.  
14 doi:10.1016/j.lungcan.2015.09.023
- 15 45. Cañadas I, Taus A, González I, Villanueva X, Gimeno J, Pijuan L, Dómine  
16 M, Sánchez-Font A, Vollmer I, Menéndez S, et al. High circulating hepatocyte  
17 growth factor levels associate with epithelial to mesenchymal transition and  
18 poor outcome in small cell lung cancer patients. *Oncotarget*. 2014;5(14):5246–  
19 56. doi:10.18632/oncotarget.2124
- 20 46. Budczies J, Klauschen F, Sinn B V., Györffy B, Schmitt WD, Darb-Esfahani  
21 S, Denkert C. Cutoff Finder: A Comprehensive and Straightforward Web  
22 Application Enabling Rapid Biomarker Cutoff Optimization. *PLoS One*.

1 2012;7(12):1–7. doi:10.1371/journal.pone.0051862

2 47. Lin F, Marcelo KL, Rajapakshe K, Coarfa C, Dean A, Wilganowski N,  
3 Robinson H, Sevick E, Bissig K-D, Goldie LC, et al. The camKK2/camKIV relay  
4 is an essential regulator of hepatic cancer. *Hepatology*. 2015;62(2):505–20.  
5 doi:10.1002/hep.27832

6 48. Depeille P, Henricks LM, van de Ven RAH, Lemmens E, Wang C-Y, Matli  
7 M, Werb Z, Haigis KM, Donner D, Warren R, et al. RasGRP1 opposes  
8 proliferative EGFR–SOS1–Ras signals and restricts intestinal epithelial cell  
9 growth. *Nat. Cell Biol.* 2015;17(6):804–815. doi:10.1038/ncb3175

10

11

1 **Figure legends:**

2 **Figure 1. Baseline Th1, Th2 and pro-inflammatory cytokines are lower in**  
3 **SCLC patients than in healthy individuals.** Dot plots showing the difference  
4 on cytokine titters between healthy volunteers ( $n = 30$ ) and patients with small  
5 cell lung cancer ( $n= 84$ ). Top of grey box shows the median value. All cytokines  
6 but IL-6 were decreased in SCLC patients when compared to a healthy  
7 population, although only in the case of IL-1 $\beta$  ( $p=0.014$ ), IL-5 ( $p=0.0013$ ), Mip-  
8 1 $\alpha$  ( $p=0.0001$ ) and TNF $\alpha$  ( $p=0.042$ ) these differences were statistically  
9 significant. Error bars show the interquartile range. GM-CSF, Granulocyte-  
10 macrophage colony-stimulating factor; IFN, interferon; IL, interleukin; MIP,  
11 Macrophage Inflammatory Protein; TNF, Tumor necrosis factor. \* $P<0.05$ ,  
12 \*\*\*\* $P<0.0001$

13

14

15

1 **Figure 2. Evolution of cytokines levels in patients treated with**  
2 **chemotherapy in combination with ipilimumab.** (A) Values correspond to  
3 median cytokine concentration, and p values were obtained taking into account  
4 the difference on the number of patients showing an increase vs decrease of  
5 cytokines levels. B, baseline; R, response; P, progression (B) Bottom of green  
6 bars reflects the variation of change of cytokine concentration from baseline to  
7 second time-point of cohort 1. Top of orange bars reflect the variation of change  
8 of cytokine concentration from baseline to second time-point of cohort 2. (C)  
9 Hierarchical clustering of changes in cytokine levels in patients treated with  
10 chemotherapy alone (top) and immunochemotherapy (bottom). The heatmap  
11 depicts the fold-change of cytokines from first to second time-point, where blue  
12 represents a decrease, and yellow and increase compared to baseline. The  
13 dominant effect is of reduction of cytokines in patients exposed to  
14 chemotherapy alone, compared to an increase in patients after  
15 immunochemotherapy. (D) Principal component analysis (PCA) showing the  
16 distribution of patients in three-dimensional space, according to changes in  
17 cytokine levels after treatment. The PCA plot shows the clustering of patient  
18 according to treatment type (chemotherapy alone, green;  
19 immunochemotherapy, orange), visualizing similarities in patterns in changes in  
20 cytokine levels. GM-CSF, Granulocyte-macrophage colony-stimulating factor;  
21 IFN, interferon; IL, interleukin; MIP, Macrophage Inflammatory Protein; TNF,  
22 Tumor necrosis factor.

23  
24

1 **Figure 3. Baseline IL-8 may be an unfavourable prognostic marker of**  
2 **response to ipilimumab in SCLC.** Patients treated either with chemotherapy  
3 alone or with ipilimumab harbouring a high baseline IL-8 had a worse OS than  
4 those with a low baseline IL-8. mOS: median overall survival.

5

6

7

1 **Figure 4. Baseline concentrations of cytokines may predict benefit from**  
2 **ipilimumab in SCLC patients.** (A) IL-2 appears to predict specific benefit from  
3 ipilimumab. (B) Patients with higher levels of IL-6 present worse OS when  
4 treated with chemoimmunotherapy but not with chemotherapy alone,  
5 suggesting a lack of benefit from ipilimumab in this subgroup. (C) Patients with  
6 higher levels of TNF $\alpha$  had a worse OS. This difference in survival was not  
7 replicated in patients treated with chemotherapy alone.  
8



1 **Figure 5. Modulation of IL-4 during treatment in SCLC could predict**  
2 **outcome.** Patients treated with chemotherapy alone whose IL-4 increased  
3 more than 23% from first to second time-point had a shorter OS, while those  
4 treated with immunochemotherapy whose IL-4 increased more than 32% had a  
5 longer OS.

6

7

1 **Supplementary figure S1.** Baseline levels of TNF $\alpha$  were significantly  
2 increased in patients over 60 years old [9.15 pg/mL vs 6.84 pg/mL ( $p=0.0067$ );  
3 IL-5 was significantly increased in patients with PS 1 or 2 vs PS 0 [2.83 pg/mL  
4 vs 1.18 pg/mL ( $p=0.047$ )]; and IL-2 was significantly increased in female  
5 patients compared with male [2.76 pg/mL vs 1.78 pg/mL ( $p=0.037$ )].

6

7 **Supplementary figure S2.** IL-4 and Mip-1 $\alpha$  were significantly decreased in  
8 patients with extensive disease when compared to those with limited disease.

9

10 **Supplementary figure S3.** Among other methods, ROC curves were calculated  
11 to evaluate its impact as a cut off parameter (see Supplementary Table S6).